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Background: There is no clinically useful score to predict chronic obstructive pulmonary disease 
(COPD) exacerbations. We aimed to derive this by analyzing data from three existing COPD 
clinical trials of budesonide/formoterol, formoterol, or placebo in patients with moderate-to-
very-severe COPD and a history of exacerbations in the previous year.
Methods: Predictive variables were selected using Cox regression for time to first severe 
COPD exacerbation. We determined absolute risk estimates for an exacerbation by identifying 
variables in a binomial model, adjusting for observation time, study, and treatment. The model 
was further reduced to clinically useful variables and the final regression coefficients scaled 
to obtain risk scores of 0–100 to predict an exacerbation within 6 months. Receiver operating 
characteristic (ROC) curves and the corresponding C-index were used to investigate the dis-
criminatory properties of predictive variables.
Results: The best predictors of an exacerbation in the next 6 months were more COPD mainte-
nance medications prior to the trial, higher mean daily reliever use, more exacerbations during 
the previous year, lower forced expiratory volume in 1 second/forced vital capacity ratio, and 
female sex. Using these risk variables, we developed a score to predict short-term (6-month) 
risk of COPD exacerbations (SCOPEX). Budesonide/formoterol reduced future exacerbation 
risk more than formoterol or as-needed short-acting β
2
-agonist (salbutamol).
Conclusion: SCOPEX incorporates easily identifiable patient characteristics and can be read-
ily applied in clinical practice to target therapy to reduce COPD exacerbations in patients 
at the highest risk.
Keywords: chronic obstructive pulmonary disease, exacerbation, model, predictor, inhaled 
corticosteroids, bronchodilators
Introduction
Exacerbations of chronic obstructive pulmonary disease (COPD) are associated 
with worse health status, more depressive symptoms, and accelerated lung func-
tion decline.1–3 COPD-related hospitalizations are a major driver of health care 
costs, accounting for around 68% of the direct medical expenses of COPD,4 and 
are independently associated with a high risk of death regardless of the severity of 
airflow limitation.5–7 Therefore, reducing exacerbations is an important goal in the 
management of COPD.8
In order to reduce future COPD exacerbations, clinicians need a clear understanding of 
how to predict exacerbation risk based on each patient’s unique characteristics.9 The stron-
gest predictor for COPD exacerbations is a previous history of exacerbation.10,11 Other 
factors that are associated with increased exacerbation risk include more severe lung dis-
ease as reflected by a lower forced expiratory volume in 1 second (FEV
1
)% predicted,11,12 





gastroesophageal reflux disease (GERD),10 poorer quality of 
life (QOL),10 chronic bronchitis,13 older age,11 lower body 
mass index (BMI),11 depression, and anxiety.14 While these 
risk factors are known, there have been few attempts to inte-
grate these findings into clinical practice. Thus, we sought to 
develop a clinically useful scoring system to assess short-term 
future exacerbation risk by analyzing easily identifiable char-
acteristics of COPD patients. To develop this score, we used 
data from clinical trials evaluating the safety and efficacy of 
budesonide/formoterol (BUD/FORM) in patients with a prior 
history of exacerbations. We identified patient characteristics 
predicting exacerbation risk in the next 6 months and assessed 
the effect of treatment on exacerbation risk.
Methods
studies and populations
The analyses used data from three double-blind, randomized, 
parallel-group, clinical studies of 6–12 months’ duration 
(NCT00206154,15 NCT00206167,16 and NCT0041974417). 
These studies investigated the efficacy of twice-daily BUD/
FORM 2×160/4.5 µg (Symbicort® metered-dose inhaler; 
AstraZeneca, Södertälje, Sweden), FORM 2×4.5 µg, and 
placebo (a short-acting β
2
-agonist [SABA]: salbutamol 
[albuterol] as needed only [2 puffs ×100 µg]) in 3,141 patients 
with moderate-to-very-severe COPD. The inclusion/ 
exclusion criteria were similar in the three studies: COPD 
patients aged .40 years, smoking history $10 pack-years, 
pre-bronchodilator FEV
1
 ,50% predicted, FEV
1
/forced vital 
capacity (FVC) ratio ,0.70, and at least one exacerbation 
in the previous year. Patients with a history of asthma were 
excluded from all three trials, by protocol, and patients were 
not permitted the use of  leukotriene antagonists throughout 
the original studies.15–17
All studies were performed in accordance with the 
 Declaration of Helsinki, Good Clinical Practice guidelines, 
and applicable regulatory requirements. All patients gave 
written, informed consent and the studies were approved by 
the Review Board for Human Subjects at each center.
Outcome variable  
and candidate predictors
COPD exacerbations were defined as worsening of COPD 
symptoms requiring treatment with oral corticosteroids 
and/or emergency department (ER) visit/hospitalization. 
Patients recorded use of oral corticosteroids, ER visits, and 
hospitalizations using diaries, which were collected at study 
visits. An exacerbation was used as the outcome to identify 
predictors of time to first COPD exacerbation.
Candidate predictors for increased risk of a future COPD 
exacerbation were selected from a range of demographic 
and baseline parameters. COPD maintenance medications 
at study entry were defined as long-acting bronchodilators 
(including theophylline), inhaled corticosteroids (ICS), and 
other daily treatments (ie, short-acting [β
2
-agonist or antimus-
carinic] bronchodilators only). The number of maintenance 
medications was assigned into categories: 0 (only short-acting 
bronchodilators), 1 (one maintenance medication), 2 (two 
maintenance medications), or 3 (three or more maintenance 
medications). Potentially relevant self-reported comorbidi-
ties and associated treatments were recorded at baseline and 
were grouped as cardiac-related morbidities (ischemic 
cardiovascular disease and arteriosclerosis), hypertension, 
diabetes, depression/anxiety, and GERD. Reliever salbutamol 
use, symptom scores, and peak expiratory flow (PEF) were 
recorded twice daily in patient diaries and summarized as the 
mean over the last 10 days of the run-in period.
statistical analyses
Predictors were identified using Cox regression analysis 
stratified by treatment and study. Univariate and multivariate 
models were used to describe the predictive properties of each 
variable individually and after adjustment for other variables 
in the model. Some highly correlated variables tested in the 
univariate model were excluded in the multivariate model, 
namely evening PEF, day- and night-time reliever use, 
St George’s Respiratory Questionnaire (SGRQ) individual 
domain scores,18 the sum of Breathlessness, Cough, and 
Sputum Scale (BCSS) scores,19 and individual comorbidities. 
The potentially non-linear nature of the risk profile of each 
identified predictor for exacerbations was described with 
linear-tailed restricted cubic splines in univariate models, 
including interaction by treatment and stratification by study. 
P-values are presented without adjustment for multiplicity; 
a conservative limit of P,0.001 was adopted as indication 
of statistical significance.
Important predictors were identified by backward selec-
tion (BWS), ranked by P-value in the logistic multiple-
regression model. The factor with the highest P-value was 
removed and the process was iterated until all remaining 
P-values were ,0.001. This resulted in a smaller multivari-
ate model supporting that all variables contribute predictive 
information. 
A simplified scoring system for the risk of an exacerbation 
within 6 months was constructed using predictors selected 
by BWS. Continuous predictors were subdivided into evenly 
distributed tertiles, corrected to clinically relevant cut-points; 
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absolute risk estimates were obtained from a binomial model 
for any exacerbation during the study, adjusting for exposure 
time. The regression coefficients were scaled to obtain score 
points, to a maximum of 100; the response function for 
6-month exacerbation risk was plotted on this scale.
To investigate the discriminatory properties of our pre-
dictors, a receiver operating characteristic (ROC) curve was 
plotted and the corresponding C-index was computed for 
the full multivariate model, including all baseline variables, 
the smaller model including the selected predictors and the 
individual predictors: post-bronchodilator FEV
1
 and number 
of exacerbations during the previous year.
Results
studies and populations
Baseline and demographic characteristics for 3,141 patients 
from the three studies15–17 are shown in Table 1. As per the 
enrolment criteria, all patients had experienced at least one 
exacerbation during the previous year. Since the treatment 
arms were not uniform in all studies, we only included 







age, years 63.1 (9.2) 63.9 (9.1) 61.7 (9.3)
BMI, kg/m2 26.7 (5.8) 26.6 (5.3) 26.9 (6.8)
Month since first COPD symptoms 130.0 (85.2) 127.0 (86.2) 124.2 (83.6)
FeV1
 Pre-bronchodilator, % predicted 34.6 (10.1) 33.6 (10.0) 36.4 (10.1)
 reversibility, % predicted 5.5 (5.9) 5.1 (5.3) 6.4 (6.7)
 Post-bronchodilator, % predicted 40.1 (12.2) 38.7 (11.8) 42.8 (12.5)
Pre-bronchodilator FeV1/FVC ratio, % 47.2 (10.6) 46.1 (10.5) 49.2 (10.6)
COPD severity (gOlD grade), n (%)
 II (moderate) 649 (20.7) 340 (16.9) 309 (27.5)
 III (severe) 1,770 (56.4) 1,159 (57.5) 611 (54.4)
 IV (very severe) 697 (22.2) 506 (25.1) 191 (17.0)
exacerbations during previous year, n (%)
 1 1,886 (60.0) 1,264 (62.7) 622 (55.3)
 2 785 (25.0) 486 (24.1) 299 (26.6)
 3 258 (8.2) 138 (6.8) 120 (10.7)
 4 120 (3.8) 74 (3.7) 46 (4.1)
 .4 92 (2.9) 55 (2.7) 37 (3.3)
smoking history
 Median, pack-years (range) 40.0 (10.0–258.0) 44.0 (10.0–258.0) 38.0 (10.0–175.0)
 Current smoker, n (%) 1,280 (40.8) 772 (38.3) 508 (45.2)
 ex-smoker, n (%) 1,861 (59.2) 1,245 (61.7) 616 (54.8)
Mean sgrQ total score (range) 55.6 (6.2–100.0) 54.4 (6.2–100.0) 57.6 (10.6–100.0)
Mean reliever use, inhalations per day (range) 4.3 (0.0–33.8) 4.2 (0.0–33.8) 4.4 (0.0–29.9)
sleep symptom score (0–4) 1.04 1.05 1.01
number of COPD medications at study entry, n (%)a
 0 803 (25.6) 495 (24.5) 308 (27.4)
 1 722 (23.0) 468 (23.2) 254 (22.6)
 2 987 (31.4) 622 (30.8) 365 (32.5)
 3 621 (19.8) 425 (21.1) 196 (17.4)
Comorbidities, n (%)b
 0 1,124 (35.8) 751 (37.2) 373 (33.2)
 1 1,119 (35.6) 739 (36.6) 380 (33.8)
 2 622 (19.8) 374 (18.5) 248 (22.1)
 .2 276 (8.8) 153 (7.6) 123 (10.9)
Notes: Data reported as mean and standard deviation, unless stated otherwise. GOLD COPD grades are defined as: grade II = post-bronchodilator FeV1 50%–80% of 
predicted; grade III = post-bronchodilator FeV1 30%–50% of predicted; and grade IV = post-bronchodilator FeV1,30% of predicted. anumber of COPD maintenance 
medications at study entry: 0= no maintenance treatment with la (long-acting β2-agonists, long-acting antimuscarinics, and theophylline), ICs, or other daily treatments 
(ie, short-acting [β2-agonist or antimuscarinic] bronchodilators only), 1= one maintenance medication, 2= two maintenance medications, 3= three or more maintenance 
medications; bcomorbidities – number of comorbidity classes (cardiac-related morbidities [ischemic cardiovascular disease and arteriosclerosis], hypertension, diabetes, 
depression/anxiety, gastroesophageal reflux disease). Data from.15–17
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, global Initiative for Chronic 
Obstructive lung Disease; ICs, inhaled corticosteroids; la, long-acting bronchodilators; sgrQ, st george’s respiratory Questionnaire.





Table 2 Backwards selection modela by Cox regression analysis of predictors for moderate and severe COPD exacerbations for all 
patients, and by sex
Baseline variable All patients (n=3,141) Males only (n=2,017) Females only (n=1,124)
HR (95% CI) Overall 
P-value
HR (95% CI) Overall 
P-value
HR (95% CI) Overall 
P-value
number of COPD maintenance medicationsb
 1 vs 0 1.18 (0.98–1.43) ,0.001 1.11 (0.86–1.42) ,0.001 1.33 (0.99–1.77) ,0.001
 2 vs 0 1.57 (1.32–1.86) 1.64 (1.31–2.06) 1.50 (1.15–1.96)
 3 vs 0 1.91 (1.59–2.30) 1.99 (1.57–2.52) 1.83 (1.35–2.47)
reliever use, number of inhalations 1.05 (1.04–1.07) ,0.001 1.05 (1.03–1.06) ,0.001 1.05 (1.03–1.08) ,0.001
number of exacerbations in the previous year
 2 vs 1 1.40 (1.21–1.61) ,0.001 1.45 (1.21–1.75) ,0.001
 3 vs 1 1.63 (1.33–2.00) 1.74 (1.31–2.31)
 4 vs 1 1.70 (1.29–2.24) 1.97 (1.40–2.79)
 .4 vs 1 2.07 (1.55–2.78) 2.22 (1.51–3.26)
sgrQ total score 1.01 (1.00–1.02) ,0.001
Pre-bronchodilator FeV1/FVC ratio (per 10%) 0.83 (0.78–0.88) ,0.001 0.98 (0.97–0.99) ,0.01 0.98 (0.97–0.99) ,0.001
sex, female vs male 1.32 (1.16–1.50) ,0.001
Notes: aBackward selection starting with all predictors and recursively removing factors with high P-value until all remaining P-values were ,0.001. The number of COPD 
exacerbations during the previous year was not selected for females alone; bnumber of COPD maintenance medications at study entry: 0= no maintenance treatment with 
la (long-acting β2-agonists, long-acting antimuscarinics, and theophylline), ICs, or other daily treatments (ie, short-acting [β2-agonist or antimuscarinic] bronchodilators only), 
1= one maintenance medication, 2= two maintenance medications, 3= three or more maintenance medications. Data from.15–17
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; hr, hazard 
ratio; ICs, inhaled corticosteroids; la, long-acting bronchodilator; sgrQ, st george’s respiratory Questionnaire.
patients who were randomized to FORM 9 µg twice daily, 
BUD/FORM 320/9 µg twice daily, or placebo.
Predictors of severe exacerbations
Univariate analysis
The baseline variables included in the univariate analysis 
to predict time to first COPD exacerbation are shown in 
Supplementary Table 1 (Supplementary material). Reliever 








and morning and evening PEF), history of exacerbations, 
number of COPD maintenance medications at entry, SGRQ 
score (total and sub-domains), Modified Medical Research 
Council (MMRC) dyspnea scale score, and the BCSS breath-
lessness score were all predictive of exacerbations. All lung 
function variables were  predictive, with the following order 
of predictive significance when sorted by P-value (highest 
to lowest): FEV
1





 . morning PEF . evening PEF 
(all P,0.001).
Multivariate analysis
Multivariate analysis, using BWS to P,0.001, identified the 
following parameters as significant predictors of increased 
exacerbation risk: more COPD maintenance medications at 
entry, higher mean daily reliever use over the last 10 days 
of run-in, more exacerbations during the previous year, 
lower pre-bronchodilator FEV
1
/FVC ratio, and female sex 
(Table 2).
In multivariate analyses stratified for males and females, 
the same predictors were found for males as for the whole 
population (Table 2). For females, the same predictors were 
found as for the whole population with one exception: the 
number of COPD exacerbations during the previous year was 
not selected, while the SGRQ total score was included.
The chosen predictors were approximately linear on a log 
scale and showed steep curves (Supplementary Figure 1). All 
lung function parameters were significant predictors, but in 
the BWS model, only pre-bronchodilator FEV
1
/FVC ratio was 
selected because it was the most significant. If pre-bronchodila-
tor FEV
1
/FVC ratio was replaced by post-bronchodilator FEV
1
, 
a similar BWS model (Supplementary Table 2) and similar 
exacerbation risks (Supplementary Table 3) were seen.
Development of risk score  
for COPD exacerbations
The score to predict short-term (6-month) risk of COPD 
exacerbations (SCOPEX) is shown in Table 3.
A comparison of ROC curves (Figure 1) shows that abil-
ity to discriminate between patients who will and will not 
have an exacerbation using the selected predictors is similar 
to the full multivariate model with all baseline variables and 
better than two commonly known individual predictors: post-
 bronchodilator FEV
1
 and number of exacerbations during the 
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Figure 1 ROC curve based on the five selected predictors (C-index =0.67), 
the full multivariate model (C-index =0.68) and the individual predictors: post-
bronchodilator FeV1 (C-index =0.62) and the number of COPD exacerbations 
during the previous year (C-index =0.62).
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced 





































Figure 2 risk of exacerbation in 6 months based on baseline risk score for each 
treatment group, with the pre-bronchodilator FeV1/FVC ratio as lung function 
predictor.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.























Notes: anumber of COPD maintenance medications at study entry: 0= no 
maintenance treatment with la (long-acting β2-agonists, long-acting antimuscarinics, 
and theophylline), ICs, or other daily treatments (ie, short-acting [β2-agonist or 
antimuscarinic] bronchodilators only), 1= one maintenance medication, 2= two 
maintenance medications, 3= three or more maintenance medications.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; ICs, inhaled corticosteroids; la, long-acting bronchodilator.
previous year. SCOPEX yielded a C-index of 0.67, which 
is similar to the selected predictors and the full multivariate 
model (0.67 and 0.68, respectively). The well-known individual 
predictors, post-bronchodilator FEV
1
 and number of exacerba-
tions during the previous year, each had a C-index of 0.62.
effects of medications  
on exacerbation risk
The 6-month exacerbation risk for a patient with a given risk 
score is shown in Figure 2. A higher risk score was associated 
with greater exacerbation risk, irrespective of randomiza-
tion to placebo (ie, SABA only), FORM, or BUD/FORM. 
The rank order (high to low) of the 6-month exacerbation 
risk was: placebo . FORM . BUD/FORM (Figure 2) over 
the range of selected predictors, as seen in the spline plots 
(Supplementary Figure 2).
Replacing the pre-bronchodilator FEV
1
/FVC ratio with 
post-bronchodilator FEV
1
 led to a similar pattern of exacer-
bation risk across the range of risk scores (Supplementary 
Figure 2).
Discussion
More COPD maintenance medications, more daily SABA 
inhalations, more exacerbations during the previous year, 
worse lung function, and female sex were the best predic-
tors of future exacerbation in this cohort of patients with 
moderate-to-very-severe COPD and at least one exacerbation 
in the previous year. Based on these readily available patient 
characteristics, we developed a scoring system to estimate 
the risk of an exacerbation over the next 6 months. This 
score may be applied in day-to-day clinical practice in such 
patients and in clinical studies to identify patients with high, 
medium, and low 6-month exacerbation risk. Clinicians can 
determine the COPD exacerbation risk score in their patients 
using an online calculation algorithm available at http://
nationaljewish.org/COPD-Calculator. The analysis included 





interventions with multiple treatments, demonstrating that 
BUD/FORM treatment reduces future exacerbation risk more 
than FORM or as-needed SABA only.
Of the identif ied predictors, worse lung function 
(FEV
1
)5,10,20–22 and a history of exacerbations10,22,23 are well-
known, strong predictors of a future exacerbation in broad 
COPD populations. Our analysis identified three more 
variables (number of maintenance COPD medications, sex, 
and daily number of short-acting bronchodilator puffs) that 
improved predictability in moderate-to-very-severe COPD 
patients. Other studies have also reported a higher exacerba-
tion risk among female patients.11 Few studies have identified 
higher reliever use as a risk factor,21 likely because most clini-
cal studies have not recorded reliever use in COPD patients.10 
Finally, the total medication load as a risk factor for exacerba-
tions is novel and has not been previously reported.





/FVC ratio, and morning and 
evening PEF) were highly significantly associated with future 
exacerbation risk in the univariate model. Pre-bronchodilator 
FEV
1
/FVC ratio was selected in the final model, probably 
because of a somewhat lower  variance.24 Reliever use is 
symptom driven and its inclusion in the model could explain 
why patient-related parameters such as SGRQ or daily 
diary symptom scores were weaker predictors of increased 
exacerbation risk. Our finding is in line with a correlation 
between reliever use loads with SGRQ and symptoms in a 
factorial analysis.25
Use of individual medications (eg, theophylline, ICS, 
and oral corticosteroids) has been reported to predict 
exacerbations and hospitalizations.22 To capture a patient’s 
total respiratory medication load, we analyzed as-needed 
SABA only and the number of maintenance long-acting 
medications used at study entry. This is the first time that 
COPD medication load, an independent predictor of similar 
significance to previous exacerbations and lung function, 
has been reported as a predictor for exacerbations. This 
likely reflects physician and patient assessment and per-
ception of symptoms, health status, exacerbation history, 
disease severity, and need for additional therapy.
Female sex was an important predictor of COPD exac-
erbations in our model. When analyzing data separately in 
males and females, predictors were identical to the whole 
population in males. In females, the multivariate analysis 
also included five predictors. In contrast, the SGRQ score 
was additionally selected in the final BWS model, whereas 
the number of exacerbations during the previous year was 
not. This sex difference confirms previous findings11 and 
may be related to differential symptom reporting (ie, females 
report worse QOL on the SGRQ26), increased symptom load 
in women, or hormonal differences.
Other patient characteristics (eg, age and BMI) did not 
predict exacerbations in our model. Age has been identified 
as a predictor of COPD exacerbations in some studies,10,21,22 
but not others.27 Likewise, the ability of BMI to predict exac-
erbations is unclear.21,27 Our finding that age and BMI do not 
predict exacerbations may be related to disease severity and 
other features of our population. Notably, adding all other 
measured clinical variables did not improve the ability to 
predict exacerbations.
Risk scoring systems for COPD exacerbations have 
been proposed previously by analysis of data from several 
 studies.22,28,29 For example, Niewoehner et al analyzed 
data from a placebo-controlled clinical trial of tiotropium 
(n=1,829) and found that FEV
1
% predicted, duration of 
COPD, a productive cough, COPD-related antibiotic or 
systemic corticosteroid use in the prior year, hospitalization 
for COPD in the prior year, and theophylline use at baseline 
were predictive of a higher risk of exacerbation, with a vali-
dated C-index of 0.66; a history of prior exacerbations was 
not required for enrolment in this study.22 Potential limita-
tions of this risk assessment method include its reliance on 
patient responses when analyzing future risk for individual 
patients. Briggs et al developed a validated composite index 
(the COPD Prognostic Index [CPI]), from a pooled analysis 
of data from 12 studies (n=8,802) to predict risk of death, 
hospitalization, or exacerbation.28 They found that the over-
all C-statistic for use of CPI in predicting both mortality 
and hospitalization was 0.71 but no prediction was given 
for future exacerbations. The CPI includes patient-reported 
QOL, assessed via SGRQ or Chronic Respiratory Question-
naire (CRQ), neither of which are routinely used in primary 
or secondary care settings. Schembri et al analyzed data 
from a prospective observational study (n=3,343) of patients 
in a community in Scotland but their model was focused 
on predicting short-term risk of death or hospitalization, 
rather than exacerbations.29 Common risk factors proposed 
by all scoring systems are airflow limitation and previous 
exacerbations.22,28,29 As with our analysis, sex was included 
as a variable by Briggs et al28 and Schembri et al,29 but not in 
the proposed scoring system by Niewoehner et al.22  However, 
in contrast to our analysis, Briggs et al28 and Schembri 
et al,29 who included a similar or greater number of patients 
as the present analysis, did not find sex to be a predictor of 
exacerbation risk. The ECLIPSE study found a significant 
relationship between female sex and exacerbation rates in 




Predicting short-term COPD exacerbation risk
univariate, but not multivariate analyses.10 The potential 
reasons for increased exacerbation rates in females are not 
clear. However, anxiety, depression, and health status are risk 
factors for COPD exacerbations30,31 and females with COPD 
appear to have higher levels of anxiety and  depression.32 
COPD exacerbations are also more common during the 
winter months, and clinicians might consider this in patient 
management.11
In contrast to the studies used to develop the scoring 
systems described above, a history of exacerbations in the 
past year was an entry requirement for patients enrolled in 
the trials used to develop SCOPEX. As previous exacerbation 
history has been previously determined to be the strongest 
predictor of future COPD exacerbation risk,10,11 the SCOPEX 
scoring system provides clinicians with a more individual-
ized approach to determining the 6-month exacerbation risk 
in patients who have experienced a prior exacerbation than 
previous models.
Our analysis was based on a large number of patients and 
provided a comprehensive analysis of risk factors relating 
to outpatient care. Nevertheless, it is important to recognize 
the limitations of our study. We carefully assembled our 
cohort from complete patient data to avoid ascertainment 
bias.  However, predictors could be different in different 
COPD phenotypes (eg, patients in our analysis were not using 
oxygen therapy). Predictors such as the SGRQ score and 
symptoms may apply in a milder group of COPD patients, 
while previous hospitalization and comorbidities could 
dominate in patients with very severe disease. Our estima-
tion of comorbidities, based on self-reported data, was not as 
rigorous as would be the case had these data been collected 
prospectively in a systematic manner or obtained from health 
care databases, although concurrent medications are likely to 
signal clinically important disease. We examined moderate-
to-very-severe COPD patients, but the largest group of 
patients had severe disease (GOLD [Global  Initiative for 
Chronic Obstructive Lung Disease] stage III),8 so our data 
may not be generalizable to the full spectrum of COPD 
patients and SCOPEX should be tested in milder COPD 
populations. All patients had experienced an exacerbation in 
the previous year, as this was one of the inclusion criteria for 
the original trials, which likely reduced the predictive power 
of previous exacerbations in this model. Additionally, data 
were collected from clinical trials so treatment adherence and 
motivation may be higher than would be seen in everyday 
clinical practice. The sensitivity and specificity are modest 
(C-index around 0.7) when applied to individual assessment; 
therefore, other clinical predictors of exacerbations should be 
sought to further improve the specificity and sensitivity of our 
scoring system. For example, we did not assess the presence 
of the chronic bronchitic phenotype, as this had not been 
identified as an exacerbation risk factor when the studies were 
conducted. A recent multivariate logistic regression analysis 
showed that pulmonary artery enlargement is associated with 
increased exacerbation risk.33 Other radiologic features (eg, 
degree of emphysema, airway wall thickness) have also been 
shown to predict exacerbations.34 Nevertheless, the C-index 
for SCOPEX shows that it is as good a predictor as a multi-
variate model including all baseline variables and superior 
to the well-established single criteria of post-bronchodilator 
FEV
1
 and the number of exacerbations in the previous year 
(C-index of 0.62 for each alone). Equally, the C-index is 
comparable with those of other tools developed for similar 
purposes. Until more accurate risk factors, such as specific 
biomarkers or radiologic features, can be identified, it seems 
unlikely that a higher level of predictive accuracy will be 
achieved with a relatively simple and easy-to-use tool such 
as SCOPEX. The SCOPEX risk score for future exacerba-
tions was developed based on data from patients enrolled in 
clinical trials; the utility of SCOPEX should be examined 
in a real-world population of patients with COPD in clinical 
practice.
In conclusion, in patients with moderate-to-very-severe 
COPD and history of prior exacerbations, more exacerba-
tions during the previous year, a lower pre-bronchodilator 
FEV
1
/FVC ratio, more maintenance respiratory medications, 
higher daily reliever use, and female sex were the strongest 
predictors for future exacerbations. Based on these variables, 
we developed a scoring system to estimate the 6-month exac-
erbation risk (available at http://nationaljewish.org/COPD-
Calculator). Furthermore, we showed that BUD/FORM 
reduces future exacerbation risk in this patient population. 
These results suggest that future exacerbation risk can be 
readily assessed in day-to-day clinical practice in moderate-
to-very-severe COPD patients, based on readily available 
clinical features. Prospective longitudinal cohort studies and 
randomized, controlled trials are needed to validate this risk 
assessment tool and scoring system to refine identification 
of patients at increased exacerbation risk.
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